SEARCH
Quotes News NAV
Merger & Demerger Markets  >  Equity  >  Corporate Actions  > Merger & Demerger
Select
Your Result on : Merger
Mahindra & Mahindra Ltd [29-May-2019]
Remarks : Mahindra Vehicles Manufacturers Ltd.
Scheme of Merger by Absorption of Mahindra Vehicle Manufacturers Limited, a wholly owned subsidiary of the Company ('MVML') with the Company and their respective Shareholders ('Scheme')
Mahindra Vehicles Manufacturers Ltd [29-May-2019]
Remarks : Mahindra Vehicles Manufacturers Ltd.
Scheme of Merger by Absorption of Mahindra Vehicle Manufacturers Limited, a wholly owned subsidiary of the Company ('MVML') with the Company and their respective Shareholders ('Scheme')
Aurobindo Pharma Ltd [28-May-2019]
Remarks : APL Healthcare Limited
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
Aurobindo Pharma Ltd [28-May-2019]
Remarks : APL Research Centre Limited
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
Aurobindo Pharma Ltd [28-May-2019]
Remarks : Aurozymes Limited
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
Aurobindo Pharma Ltd [28-May-2019]
Remarks : Hyacinths Pharma Private Limited
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
Aurobindo Pharma Ltd [28-May-2019]
Remarks : Silicon Life Sciences Private Limited
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench).
Kintech Renewables Ltd [28-May-2019]
Remarks : Divine Windfarm Pvt Ltd
Intimation under Regulation 30 and 37(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015('Listing Regulations'), as amended from time to time - Scheme of Amalgamation
Repro India Ltd [28-May-2019]
Remarks : Repro Innovative Digiprint Ltd
Dear Sir / Madam, The Board of Directors of the Company at their meeting held today i.e. May 28, 2019 has considered and approved the following matters: Demerger of Printing Business of Repro Innovative Digiprint Limited (Wholly owned Subsidiary) into Repro India Limited subject to the approval of the members of the Company and the regulatory authority.
APL Research Centre Ltd [28-May-2019]
Remarks : APL Research Centre Ltd
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please take note that Board of Directors ('Board') of the Company at its meeting held on May 28, 2019, considered and approved the Scheme of Amalgamation ('Scheme') pursuant to sections 230-232 and other applicable provisions of the Companies Act, 2013, providing for the amalgamation of its wholly owned subsidiaries viz.,APL Healthcare Limited, APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and Silicon Life Sciences Private Limited ('Transferor Companies') with Aurobindo Pharma Limited ('Transferee Company'). The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench)
<< < 1 2 3  ... > >>